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INTRODUCTION
The pathophysiology of acute spinal cord injury (SCI) is
characterized by an initial, mechanical injury (primary injury),
followed by a series of secondary injury events including
ischemia, calcium- and sodium-mediated cellular injury, ex-
citotoxic cell death, inflammation, and apoptosis. A variety
of promising substances have been tested in animal models
of acute SCI, but few have had potential application to human
SCI patients. Methylprednisolone (MP) and GM-1 ganglio-
side have met rigorous criteria in laboratory testing and initial
human investigations. Although the National Acute Spinal
Cord Injury Studies (NASCIS) II and III advocated the clin-
ical use of MP for acute SCI, critical reviews and contradict-
ing studies have cast doubts on its efficacy (1-3). After NASCIS
II study, many clinical researches have shown that MP admin-
istered according to the NASCIS regimen failed to improve
outcome at least in moderate-to-severe cord injuries (4-8).
Thus, the beneficial effect of MP may not be great enough
to advocate it as the standard of care for acute SCI. 
Recent study has shown that MP depresses the production
of growth-promoting factors such as brain-derived neurotroph-
ic factor (BDNF) and neurotrophin-3 (NT3) following acute
SCI (9). This suggests the possibility that, while MP prevents
secondary injury in the acute stage of SCI through various
mechanisms, including inhibition of lipid peroxidation, calci-
um influx, ischemia, axonal dieback, calpain-mediated cyto-
skeletal degradation, and anti-inflammatory effects, it may
hinder functional recovery after the acute stage, especially in
severe spinal cord injuries. Thus, the combination of MP with
other pharmacological agents that can promote functional
recovery is desirable. Some studies have tested combination
treatments but have focused on secondary injury reactions
or on promoting regeneration rather than influencing both
the acute and chronic stage following SCI.
The ability of growth factors to promote axonal regenera-
tion in injured spinal cord has been extensively studied. BDNF
is one of the best-characterized of the neurotrophic factors.
The neurotrophic activity of BDNF has been studied in var-
ious models of central nervous system (CNS) injury, such as
spinal cord trauma, contusion injury, and spinal cord hemi-
section and axonal lesion. It has been shown to enhance sur-
vival and to stabilize both sensory and motor neurons (10, 11).
Recent study has shown functional evidence that BDNF is
an anterograde neuronal trophic factor in the CNS of the adult
rat (12). 
Adjunct neurotrophic factor, such as BDNF, combined
with initial MP treatment may enhance functional outcome
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Continuous Brain-derived Neurotrophic Factor (BDNF) Infusion After
Methylprednisolone Treatment in Severe Spinal Cord Injury
Although methylprednisolone (MP) is the standard of care in acute spinal cord injury
(SCI), its functional outcome varies in clinical situation. Recent report demonstrated
that MP depresses the expression of growth-promoting neurotrophic factors after
acute SCI. The present study was designed to investigate whether continuous infu-
sion of brain-derived neurotrophic factor (BDNF) after MP treatment promotes func-
tional recovery in severe SCI. Contusion injury was produced at the T10 vertebral
level of the spinal cord in adult rats. The rats received MP intravenously immediately
after the injury and BDNF was infused intrathecally using an osmotic mini-pump for
six weeks. Immunohistochemical methods were used to detect ED-1, Growth asso-
ciated protein-43 (GAP-43), neurofilament (NF), and choline acethyl transferase
(ChAT) levels. BDNF did not alter the effect of MP on hematogenous inflammatory
cellular infiltration. MP treatment with BDNF infusion resulted in greater axonal sur-
vival and regeneration compared to MP treatment alone, as indicated by increases
in NF and GAP-43 gene expression. Adjunctive BDNF infusion resulted in better
locomotor test scores using the Basso-Beattie-Bresnahan (BBB) test. This study
demonstrated that continuous infusion of BDNF after initial MP treatment improved
functional recovery after severe spinal cord injury without dampening the acute effect
of MP. 
Key Words : Regeneration; Brain-Derived Neurotrophic Factor; Methylprednisolone; Spinal Cord Injuries 
Received : 21 May 2003
Accepted : 9 October 2003114 D.H. Kim, T.-A. Jahng
by preventing secondary injuries and by promoting neuronal
regeneration. This study was designed to test this possibility
in a contusion-injury model in the rat spinal cord. Combina-
tion therapy was compared to no other treatment but to MP
treatment alone.
MATERIALS AND METHODS
Spinal Cord Contusion Injury
Forty-five adult female Sprague-Dawley rats weighing 200-
250 g were maintained under standard conditions at the Uni-
versity Animal Care System. Spinal cord contusion injuries
were performed using the UCSF spinal cord injury model.
Spinal cord injury model was tested several times with patho-
logic examination, as well as neurological deficit to properly
induce severe spinal cord injury. Rats were anesthetized with
ketamine (60 mg/kg) and xylazine (10 mg/kg) injected int-
raperitoneally. The lamina and spinous process of T10 were
removed to expose a circular region of dura measured at app-
roximately 2.8 mm in diameter. The spinous processes of T9
and T11 were clamped with tissue forceps, which in turn
were held by Kopf rat spinal clamps, to stabilize the spinal
column. The clamps were then raised so the thoracic region
of the rat was suspended by the spinous processes. The animals
were positioned under a 10-g weight device, which consisted
of a Teflon impounder loosely fitted over the end of a brass
rod and attached to a three-dimensional stereotaxic frame. A
brass rod was inserted through the weight, which was secured
by a removable pin. The impounder was centered over the
laminectomy and was lowered onto the dura. The weight
dropped by 5 cm when the pin was pulled to make contusion
injury onto T10 level. Five seconds later, the entire rod assem-
bly was raised off the dura. After sustaining the contusion
injury, the muscles of the rat were sutured over the laminec-
tomy site, and the skin was closed with wound clips. Post-
operatively, the rats received a 5-mL subcutaneous injection
of saline and an intramuscular injection of gentocin (2.5 mg)
daily, and their bladders were expressed twice daily until reflex-
es returned. The rats were maintained in pairs in separate cages.
Twenty-seven rats (3 rats per group for 1, 3, 7 days after injury
respectively) were used for RT-PCR and eighteen rats (6 rats
per group) were used for functional assessment.
MP Treatment and BDNF Infusion
The rats were divided into control, MP only (+ placebo
infusion), and MP+BDNF infusion groups. Control rats were
not treated after spinal cord contusion injury. For MP treat-
ment, rats received 60 mg/kg MP intravenously immediately
after SCI, and four hours later they received 30 mg/kg MP
intravenously. For MP+BDNF treatment, BDNF (Alomone
Co., Israel) was dissolved in an artificial cerebrospinal fluid
(CSF) solution (Na+ 150 mM, K+ 3 mM, Ca2+ 1.4 mM, Mg2+
0.8 mM, phosphate 1 mM, Cl- 155 mM) at a concentration
of 0.33 mg/mL. Each rat was implanted with an osmotic
minipump-brain infusion assembly for continuous infusion
(placebo or BDNF) of the injured site (Alzet, Palo Alto, CA,
U.S.A.; Model 2004, mean pumping rate=6  L/day). The
brain infusion assembly consisted of a catheter tube (2.5-cm
length) and a stainless steel cannula with adjustment spacers
to obtain the correct stereotaxic depth. The cannula was filled
with the appropriate solution and connected to the pump.
The entire device was incubated in sterile saline at 37℃ for
at least 40 hr prior to surgery in order to ensure immediate
flow of the solution once the pump was inserted in the rats.
Following the contusion injury, the cannula was inserted
intrathecally at the injury site under surgical magnification
using loupe and was secured by sutures. The osmotic pump
was housed in a subcutaneous pocket in the back of the rat
and was infused maximally for six weeks. Rats were subse-
quently sacrificed and evaluated at the interval of one, three,
and seven days, and then at ten weeks of post injury. 
Immunohistochemical Analysis
The anesthetized rats were perfused with cold 0.1 M, pH
7.2 PBS containing heparin, and then perfused with 4%
buffered paraformaldehyde. Spinal cord from the contused
site was cut and fixed in a 10% formalin solution for two
hours, embedded in paraffin, then cut in 4- m sections for
immunohistochemical staining. Briefly, the sections were
treated with 0.3% H2O2 in methanol to inactivate the endoge-
nous peroxidase, and nonspecific staining was blocked with
a solution of 3% normal serum. Primary antibodies raised
against ED-1 (rabbit anti-ED-1, Serotech, U.K., 1:1,000);
NF (mouse anti-Neurofilament SMI31, Sternberger Mono-
clonals, Baltimore, MD, U.S.A., 1:1,000); growth associated
protein-43 (GAP-43, Chemicon, 1:1,000); and choline acetyl
transferase (goat anti-ChAT; Chemicon, 1:500) were diluted
in 1% normal serum, applied to the tissue sections for one
hour at 37℃, and then applied to the tissue sections overnight
at 4℃. Sections were incubated with an appropriate biotiny-
lated secondary antibody (1:200, Vector laboratories, Burlin-
game, CA, U.S.A.) followed by ABC complex for 45 min at
room temperature. Diaminobenzidine (DAB-brown color;
Sigma Chemical Co., St. Louis, MO, U.S.A.) was used as the
chromatogen. The sections were counterstained with hema-
toxylin, dehydrated in graded alcohols, and mounted. Sections
were also stained with appropriate normal serum for control
comparison. Omission of primary antibodies resulted in only
weak, nonspecific labeling of the blood vessels. Quantification
of the proportional area at the center of the lesion at a mag-
nification level of 40× was performed by using a computer-
assisted digital image analysis system (Image Measure/IP Ver.
4.0-NIH image program), and by manually setting the rel-
ative optical density threshold to identify positive stainedproperties within a defined target area.
Reverse Transcriptase Polymerase Chain Reaction 
(RT-PCR)
Gene expression of growth-associated protein 43 (GAP-43),
an endogenous indicator of axonal regeneration, was assessed
by RT-PCR on one, three, and seven days following the con-
tusion injury. Each therapy test group consisted of three ani-
mals. Briefly, total cellular mRNA was isolated from the injury
area at the different intervals by using AMV reverse transcrip-
tase. The resulting cDNA was amplified by using the specific
primer for GAP-43 (Upstream primer: AAGAAGGCAGGG-
GAAGATAC; Downstream primer: GGACGGCGAGTTA-
TCA GTGG). Quantification of mRNA levels was performed
as previously described (13).
Behavioral Assessment
A total of 18 animals were used to investigate neurological
functional recovery following SCI. Using the Basso, Beattie,
and Bresnahan (BBB) scale (14), functional assessment of
locomotion was performed by observers blinded to treatment
methods. Rats were trained preoperatively each week in an
open field that consisted of a plywood circular enclosure with
a smooth non-slip floor. Open field training and testing proce-
dures were done exactly as described in Basso et al. Rats were
evaluated every week following injury and treatment. 
Statistics
To determine whether differences in functional recovery
were statistically significant, the data were examined by using
a computerized statistical analysis program (SPSS 9.0 for Win-
dows, SPSS Inc.). Histological outcome measures were ana-
lyzed by using univariate ANOVA. If the main effects were
significant, then outcomes were assessed by using Tukey’s
HSD test. Behavioral measures were compared using a gen-
eral linear model with repeated measures. If ANOVA inter-
action effects (group×time) were significant (p<0.05), post
hoc pairwise comparisons were performed by using Tukey’s
HSD to compare groups at each point. Significance for all
analyses was set at p<0.05.
RESULTS
Immunohistochemical analyses of spinal cord tissue after
contusion injury were performed to compare the effects of
the treatments on three variables: the extent of hematogenous
inflammatory cellular infiltration (as indicated by ED-1 im-
munoreactivity), the extent of axonal regeneration (as indicated
by NF and GAP-43 immunoreactivity), and the extent to
which regeneration occurred in cholinergic axons (as indicat-
ed by ChAT immunoreactivity).
Hematogenous Cell Infiltration
To assess infiltration of the contusion site by hematogenous
cells (monocytes/macrophages), paraffin-embedded spinal
cord tissue in the center of the contusion was immunostained
with ED-1 antibody (15). During early stage (1, 3 & 7 days)
after the injury, ED-1-positive cells increased substantially
(Fig. 1A). Significantly fewer ED-1-positive cells were seen
at the contusion site in the MP-only and MP+BDNF-infused
animals (Fig. 1B, C). This difference was found to have sta-
tistical significance after quantification of the injury area was
performed using the computer-assisted image analysis system
(Fig. 1D; p<0.05). 
Axonal Survival and Regeneration 
To evaluate axonal survival and regeneration, neurofilament
(NF) and GAP-43 immunoreactivity were assessed at ten
weeks of post injury. The significantly more NF-positive
axons survived in the MP+BDNF-infused group (Fig. 2C)
than in MP-only and control groups (Fig. 2A, B, D; p<0.05).
More GAP-43-positive neurites were also observed in the
MP+BDNF-infused spinal cord (Fig. 3C) compared to the
other two groups (Fig. 3A, B, D; p<0.05). 
Motor Axonal Regeneration 
To identify the phenotype of regenerating fibers, ChAT
immunoreactivity was assessed. As shown in Fig. 4, ChAT
staining showed that motor axons predominated in axonal
regeneration, and the MP+BDNF-infused group (Fig. 4C)
regenerated many more motor axons than did the MP-only
and control groups (Fig. 4A, B, D; p<0.05). 
GAP-43 Gene Expression
Neuronal fibers and regenerated axons both express NF
and GAP-43. To demonstrate whether axonal regeneration
actually occurred, we compared early gene expression of GAP-
43, an endogenous indicator of axonal regeneration, in the
different therapeutic groups. Injured spinal cord groups were
infused with MP+BDNF, MP only, or were untreated, at the
intervals of one, three, and seven days. The effects on GAP-
43 gene expression were examined at each interval using RT-
PCR. The largest difference was observed during the first day.
RT-PCR revealed a 23.4±3% increase in GAP-43 gene
expression in the MP+BDNF infused group, while no changes
were detected in the MP-only and control groups (data not
shown). There were no significant differences between the
MP+BDNF and MP-only groups at days three or seven,
although GAP-43 gene expression in both groups was still
higher than it was in control group.
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Functional Recovery
Unfortunately, some of the rats died of cystitis or other infec-
tions, so the number surviving ten weeks after SCI was five
in the BDNF+MP group, five in the MP-only group, and
four in control group. Observers blinded to the treatments
performed all functional assessments and analyses, using the
BBB open field locomotion scale. The MP-only group and
control groups uniformly exhibited either paralysis or occa-
sional uncoordinated hindlimb spasms. Three weeks after
SCI, initial paralysis was attenuated in animals infused with
MP+BDNF. Six weeks after injury, they demonstrated exten-
sive joint movement in their hindlimbs, and their BBB score
increased significantly relative to MP-only and control groups
(Fig. 5, p<0.05). Rats in the MP-only group were not signif-
icantly different from the control group.
DISCUSSION
Spinal cord contusion injury is a standard model for investi-
gating neuron injury and regeneration. Authors evaluated the
Fig. 1. Immunohistochemical staining for ED-1 at the contusion injury site (×40). 3 days after the SCI, many ED-1-positive inflammatory
cells (stained with brown color) are observed at the contusion site in the untreated spinal cord (A). In contrast, ED-1-positive inflammatory
cells are markedly decreased in the MP-only (B) and MP+BDNF (C) infused animals. This difference, represented as means±S.D. in (D),
is significant (p<0.05).
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*effects of a combination therapy of acute MP and continuous
BDNF infusion on the initial anti-inflammatory reaction,
axonal regeneration, and functional recovery. Immunostain-
ing revealed a reduction in ED-1-positive inflammatory cells
infiltrating the contusion site in MP and MP+BDNF groups.
Concomitantly, increased motor neuron regeneration and func-
tional improvement were observed in the MP+BDNF group,
compared to MP-only and control groups. Increased GAP-43
gene expression was seen in spinal cords from the rats in the
MP+BDNF group one day after SCI. To our knowledge, this
report is the first to demonstrate that a combination therapy
of MP and BDNF can reduce the initial inflammatory reaction,
and boost axonal regeneration following SCI.
After the primary injury, the spinal cord lesion is enlarged
by secondary inflammation, causing further injury. Since the
activated macrophages and microglia release cytotoxic sub-
stances that participate in secondary post-injury tissue destruc-
tion, an important treatment issue is how to control initial
inflammatory reactions following SCI. In this study, ED-1
was chosen as a marker to identify the presence of infiltrating
cells (15). ED-1-positive cells in immunostained sections of
injured spinal cords decreased dramatically and evenly in rats
treated with MP alone or MP combined with BDNF infusion.
In contrast, more ED-1-positive inflammatory cells infiltrated
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Fig. 2. Immunohistochemical staining for NF at the contusion injury site (×40). Ten weeks after SCI, fewer NF-positive neuronal fibers are
observed at the lesion in the control (A) and MP-only groups (B). More NF-positive neuronal axons survive in the spinal cords of rats in the
MP+BDNF group (C). This difference, represented as means±S.D. in (D), is significant (p<0.05).
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NFthe injury site in untreated animals. MP with BDNF infusion
keeps potent anti-inflammatory effects in the spinal cord con-
tusion model, consistent with previous reports (16). Thus,
adjuvant BDNF infusion did not affect the MP action on
spinal cord, at least in terms of most important anti-inflam-
matory effect in acute stage of SCI.
High-dose corticosteroid may exert several detrimental
effects on neurological recovery (4, 17). By inhibiting immune
cell activity and antigen processing by macrophages, corticos-
teroid may interfere with neuronal regeneration. Glucocor-
ticoids may also exacerbate postischemic neuronal necrosis
and inhibit axonal sprouting. Some studies have shown that
MP depresses the production of growth-promoting factors
such as BDNF and NT3 (9). Thus, MP treatment alone has
not been sufficient, or may hinder, functional recovery follow-
ing SCI. Therefore, we thought it reasonable to combine nerve-
growth factor with MP after acute SCI. The more NF-posi-
tive neuronal axons and the GAP-43-positive neurites were
observed in spinal cords of MP+BDNF rats compared to MP-
only and untreated rats, which suggests that neurons were
rescued. GAP-43 immunoreactivity has been used to evalu-
ate regenerating axons (18, 19). There is a close correlation
between GAP-43 expression and successful regeneration of
CNS neurons (20, 21). GAP-43 is concentrated at the axon-
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Fig. 3. Immunohistochemical staining for GAP-43 at the contusion injury site (×40). Ten weeks after SCI, many GAP-43-positive neurites
are found in the MP+BDNF group (C), while few are detected in the control (A) and MP-only treated (B) rats. This difference, represented
as means±S.D. in (D), is significant (p<0.05).
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*al growth cone, where it seems to play an important role in
the transduction of growth cone guidance signals (18, 19). In
this study, we hypothesized that significant numbers of GAP-
43 positive neurites in the MP+BDNF infused spinal cords
could be interpreted as effective axonal regeneration. In addi-
tion, most regenerating fibers were ChAT-positive motor neu-
rons, and many more such fibers were observed in spinal cords
infused with BDNF compared to other two groups. These
results are consistent with previous reports (22).
We also investigated GAP-43 gene expression to determine
whether axonal regeneration actually occurred. Quantitative
RT-PCR revealed a 23.4±3% increase in GAP-43 gene ex-
pression at the injured site one day following MP+BDNF
infusion, while no significant changes in GAP-43 gene expres-
sion were detected in the MP-only treated and control animals.
This suggests that BDNF has the ability to enhance axonal
regeneration in the early phase of acute SCI, consistent with
recent reports (23).
In addition to immunohistochemical studies, we observed
the effects of long-term infusion of BDNF on behavioral recov-
ery, using the BBB open field locomotion scale. MP+BDNF
treatment resulted in extensive hindlimb movements with
weight support in almost all animals ten weeks after SCI.
Animals infused with MP only and untreated control animals
did not exhibit extensive hindlimb movement. Three weeks
after SCI, the BBB scores increased more in the MP+BDNF
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Fig. 4. Immunohistochemical staining for ChAT at the contusion injury site (×40). More ChAT-positive axons appear in MP+BDNF rats (C)
ten weeks after SCI than in the other two groups (A, B). This difference, represented as means±S.D. in (D), is significant (p<0.05).
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ChATinfused rats compared to MP-only treated and untreated rats.
Various forms of alternating hindlimb stepping or locomotor
activity have been obtained in rats, cats, and humans following
SCI. In the present study, animals treated with MP+BDNF
exhibited active hindlimb movement, which is related to
motor neuron regeneration stimulated by BDNF. It is thought
that hindlimb activity is controlled within the lumbar spinal
cord by interneuronal networks collectively referred to as cen-
tral pattern generators (CPGs) (24). The effect of BDNF might
be to reduce the activation threshold for existing CPGs, in
addition to promoting axonal regeneration (25).
Contrary to several reports, animals treated with MP alone
did not show good functional recovery in our study. Although
scores of some of the MP-treated animals were statistically
different at some points from control animals and it showed
progressive recovery with time, this was not a consistent effect.
Furthermore, behavioral recovery curve generated for MP only
treatment is virtually identical to that of control. This sug-
gests that MP affects SCI during the acute phase only, and
has little effect on long-term functional recovery. This may
be related to the fact that MP reduces the growth factors and
interfere neuronal regeneration and axonal sprouting (4, 9,
17), but it may also reflect the severity of the injury. Four ani-
mals were lost during this study, and overall levels of function
were not as high as reported by others. This may suggest that
MP is less effective in severe SCI; it is not unusual in clinical
situations for patients with severe SCI to fail to respond to
mega-dose MP treatments, despite an appropriate therapeu-
tic time window (5-8). It also suggests that continuous BDNF
therapy may be more important than MP for long-term func-
tional recovery. 
The mechanisms of the recovery-enhancing effects of BDNF
may be related to the fact that BDNF interacts with TrkB,
a member of the trk receptor family, which transduces BDNF
signaling in responsive neurons (26) . TrkB receptor is exp-
ressed not only in developing motor neurons, but in mature
motor neurons as well (27-29). Adult motor neurons have
been shown to retrogradely transport BDNF in a receptor-
mediated fashion (30) . The first evidence of this was the obser-
vation that administration of exogenous BDNF markedly
attenuated the decrease of ChAT immunoreactivity in adult
facial motor neurons (31, 32), and in adult spinal motor neu-
rons following distal axotomy (33). Subsequently, BDNF was
shown to prevent cell death of adult motor neurons (34). How-
ever, previous studies showed that this effect was transient
because little effect was seen two to three weeks post injury.
Our study suggests that exogeneously administered BDNF
attenuated the decrease of ChAT immunoreactivity, and pro-
moted axonal outgrowth of injured adult motor neurons ten
weeks following SCI. The neurotrophic effect of BDNF was
shown to be long-lasting in adult motor neurons.
In spite of encouraging results, this study has several lim-
itations. It was intended to test new therapeutic method,
which is simulated clinical situation, it is necessary to iden-
tify whether chronic BDNF infusion without initial MP treat-
ment can evoke similar outcome compared to MP+BDNF
infusion. Although MP+BDNF enhanced hindlimb step-
ping and improved functional recovery following SCI, it was
not enough recovery to walk. It might reflect an increase in
reflexive movements that may not associated with motor axon
regeneration because BDNF alone can cause reflexive air walk-
ing in transection model (25). These will be elucidated with
further experiments. Immunohistopathologic technique in
this study is semi-quantitative, usually used in clinical pathol-
ogy. Thus, further experiment using precise quantitative tech-
nique is necessary to support motor axonal regeneration. 
In summary, this study demonstrated that a combination
therapy of MP+BDNF not only attenuated hematogenous
inflammatory cell infiltration, but also enhanced motor axon
regeneration following SCI. The present study offers a ratio-
nal approach for the treatment of spinal cord injury in which
both the attenuation of initial injury and the regeneration of
motor axons are required. Further studies are needed to eval-
uate the proper concentration and duration of BDNF infu-
sion on a large number of animals that have sustained mod-
erate SCI via other means.
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Fig. 5. BBB (Basso Beattie Bresnahan) locomotor score (means
±S.D.). Rats that received MP+BDNF revealed active coordinat-
ed hindlimb movement, six weeks after SCI. The MP-only and
untreated rats exhibited either paralysis or occasional uncoordi-
nated hindlimb spasms ten weeks after SCI. Differences each
week were determined by post hoc means-corrected t-tests
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